UNSPSC 51181923: Nitromifene

This classification denotes an antiestrogen with the molecular formula C27H28N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5FS1NJ6Q8N chemically known as pyrrolidine, 1-(2-(4-(1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl)phenoxy)ethyl)- but generally known as nitromifene, which bears US NIH Compound Identifier 3032557. European Medicines Agency schedules Nitromifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09327MIG.

UNSPSC 51181923 Nitromifene, a Commodity code, represents pharmaceutical products that state and local governments procure through cooperative purchasing agreements and multistate health system contracts. The work being solicited under this code involves supplying generic and over-the-counter pharmaceuticals meeting FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements, with detailed product specifications including National Drug Codes, SKUs, UPCs, dosage forms, and manufacturing locations. State and local buyers—typically health departments, correctional systems, state employee health plans, and participating county and municipal health facilities—source these products through authorized pharmaceutical wholesalers under master agreements that establish pricing structures, administrative fee arrangements, and performance penalties. Vendors must maintain robust insurance coverage (workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000) and demonstrate the ability to deliver products with at least one-year expiration dates and six-month minimum shelf life.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 effective date for awarded contracts. The RFP serves participating state and local facilities across Minnesota and Oregon, requiring vendors to establish relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and to submit pricing in formats including flat price, net price, or WAC-minus structures. Evaluation weights pricing competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). No specific dollar ceiling or set-aside designations were disclosed; contract terms run two years for new vendors with optional extensions at MMCAP's discretion, while incumbent amendments extend through June 30, 2028.